Edgewise Therapeutics, Inc. - EWTX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G | JANUS HENDERSON GROUP PLC | 5.5% | 5,915,556 | View |
| Apr 27, 2026 | SCHEDULE 13D/A | — | 4.9% | — | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Paradigm BioCapital Advisors LP | 6.2% | 6,541,210 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Paradigm BioCapital Advisors GP LLC | 6.2% | 6,541,210 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Senai Asefaw, M.D. | 6.2% | 6,541,210 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Paradigm BioCapital International Fund Ltd. | 5.5% | 5,778,924 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.